Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
201.18 ^USD	+8.53%		+11.84%	+14.31%

02:06am	Biogen says biologics license application for subcutaneous formulation of Leqembi for treatment of early Alzheimer's disease designated for Priority Review in China	RE
02-06	Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating	MT

Transcript : Biogen Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01

Published on 01/12/2026 at 10:36 pm GMT - Modified on 01/13/2026 at 12:35 am GMT

S&P Capital IQ

Presenter Speech
Christopher Schott (Analysts)

Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Biogen today. We have the company's CEO, Chris

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Biogen Inc.

02:06am	Biogen says biologics license application for subcutaneous formulation of Leqembi for treatment of early Alzheimer's disease designated for Priority Review in China	RE
02-06	Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating	MT
02-06	Biogen Inc., Q4 2025 Earnings Call, Feb 06, 2026
02-06	Biogen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-06	Stocks Gain Pre-Bell as Wall Street Eyes Recovery After Selloff	MT
02-06	Biogen Q4 Non-GAAP Earnings, Revenue Fall; 2026 Outlook Set -- Shares Up Pre-Bell	MT
02-06	(BIIB) Biogen Expects 2026 Adjusted EPS Range $15.25 to $16.25, vs. FactSet Est of $14.93	MT
02-06	Earnings Flash (BIIB) Biogen Posts Q4 Total Revenue $2.28B, vs. FactSet Est of $2.20B	MT
02-06	Earnings Flash (BIIB) Biogen Posts Q4 Adjusted EPS $1.99, vs. FactSet Est of $1.63	MT
02-06	Biogen sees 2026 adj EPS $15.25 - $16.25 versus IBES estimate $14.92	RE
02-06	North American Morning Briefing : Futures Point to Gains After Thursday's Slide -2-	DJ
02-06	Eisai Co Ltd - revenue of Leqembi (preliminary basis)	RE
02-06	Biogen forecasts upbeat annual profit, eyes 2028 launch of key drugs	RE
02-04	Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy	CI
02-03	Bernstein Adjusts Biogen Price Target to $191 From $197	MT
01-30	Oppenheimer Adjusts Biogen Price Target to $225 From $205, Maintains Outperform Rating	MT
01-30	Oppenheimer Raises Price Target on Biogen to $225 From $205, Keeps Outperform Rating	MT
01-28	Biogen Says Cutaneous Lupus Erythematosus Treatment Granted US FDA Breakthrough Therapy Designation	MT
01-28	Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease with No Targeted Treatment Options	CI
01-28	Biogen Gets FDA Breakthrough Designation for Litifilimab in CLE	DJ
01-27	Citigroup Adjusts Price Target on Biogen to $185 From $180, Maintains Neutral Rating	MT
01-26	Sector Update: Health Care Stocks Advance Late Afternoon	MT
01-26	Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®?	CI
01-26	Sector Update: Health Care	MT
01-26	Planting Hedges Early